Leading Companies Consolidating Their Presence in the Antisense and RNAi Therapeutics Market

The antisense and RNAi therapeutics market is rapidly evolving as cutting-edge technologies and precision medicine drive innovation in disease treatment. With a growing number of clinical trials and increasing investments globally, this sector is set to experience substantial growth. Here is an overview of the market's size, key players, emerging trends, and segmentation to provide a clear picture of its future trajectory.

Antisense and RNAi Therapeutics Market Size Forecast Through 2030
The antisense and RNAi therapeutics market is projected to expand significantly, reaching a valuation of $3.53 billion by 2030. This reflects a robust compound annual growth rate (CAGR) of 12.9% during the forecast period. Factors contributing to this surge include advancements in drug delivery technologies, broader adoption of precision medicine, the integration of artificial intelligence in drug discovery, a rise in RNAi-based clinical trials, and increasing healthcare spending in emerging economies. Key trends expected to influence the market include targeted gene silencing techniques, innovative delivery methods, personalized therapeutic approaches, improved nucleic acid stabilization, and progress in regulatory and clinical frameworks.

Download a free sample of the antisense & rnai therapeutics market sample:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3389&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Prominent Players Leading the Antisense and RNAi Therapeutics Sector
The market includes several influential companies pioneering advancements in this field. Major players are Biogen Inc., Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Moderna Inc., Sanofi S.A., Dicerna Pharmaceuticals Inc., Arbutus Biopharma Corporation, Acuitas Therapeutics, Adhera Therapeutics Inc., EdiGene Inc., Sirnaomics Inc., Suzhou Ribo Life Science Co. Ltd., Biocon Limited, Quark Pharmaceuticals, GlaxoSmithKline Plc, Shanghai Junshi Biosciences Co. Ltd., AstraZeneca, Benitec Biopharma Limited, Silence Therapeutics, Dynacure, CN Bio Innovations, Sarepta Therapeutics, Mallinckrodt, Regeneron Pharmaceuticals Inc., Alcyone Lifesciences Inc., Bio-Path Holdings Inc., Calando Pharmaceuticals, Enzon Pharmaceuticals Inc., Celnova Pharma, Pfizer Inc., Taiba Pharma, Gen Ilaç ve Saglik Ürünleri A.S., and Egypt Otsuka Pharmaceutical.

Strategic Collaborations Highlighting Market Innovation
Collaborations and partnerships are becoming essential strategies for companies to maintain a competitive edge in the antisense and RNAi therapeutics landscape. For example, in July 2023, Alnylam, a US-based biopharmaceutical firm specializing in RNAi therapies, announced a strategic alliance with Roche AG. They plan to jointly develop and commercialize Zilebesiran, an investigational RNAi therapeutic targeting hypertension in patients with elevated cardiovascular risk. This partnership merges Alnylam's RNAi expertise with Roche's extensive drug development and commercialization capabilities, potentially opening new avenues for treating cardiovascular conditions. Roche AG is headquartered in Switzerland and is known for its focus on therapies addressing cardiovascular diseases.

View the full antisense & rnai therapeutics market report:
https://www.thebusinessresearchcompany.com/report/antisense-and-rnai-therapeutics-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Collaborative Efforts Driving Innovation in RNAi Therapeutics
Further emphasizing the market's collaborative momentum, January 2023 saw Orbit Discovery Limited, a US company focused on peptide discovery, team up with SanegeneBio Inc., a UK-based developer of novel RNAi medicines. Their partnership aims to identify tissue-specific delivery mechanisms for RNA therapeutics to achieve efficient gene knockdown. This joint effort involves hit identification and cell-based internalization studies, with SanegeneBio holding the option to advance promising candidates from Orbit's screening activities. Orbit Discovery employs a proprietary peptide display technology capable of rapidly screening large peptide libraries, accelerating the discovery of targeted leads based on both affinity and functional performance.

Breakdown of the Antisense and RNAi Therapeutics Market by Segments
The global antisense and RNAi therapeutics market is segmented as follows:
1) Technology: RNA Interference, Antisense RNA
2) Route of Administration: Intravenous Injections, Intra-dermal Injections, Other Delivery Methods
3) Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other Indications

Further subcategories include:
- For RNA Interference (RNAi): Small Interfering RNA (siRNA), Short Hairpin RNA (shRNA), Dicer-substrate siRNA, MicroRNA (miRNA)-Based Therapeutics
- For Antisense RNA: Antisense Oligonucleotides (ASOs), Morpholino Oligomers, Locked Nucleic Acids (LNAs), Gapmer Antisense Oligonucleotides

This detailed segmentation highlights the diverse approaches and therapeutic targets within the antisense and RNAi field, underscoring its potential to address a wide range of medical conditions.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.